110 related articles for article (PubMed ID: 20197637)
21. Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C.
Zhang JS; Imai T; Suenaga A; Otagiri M
Int J Pharm; 2002 Jun; 240(1-2):23-31. PubMed ID: 12062498
[TBL] [Abstract][Full Text] [Related]
22. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
Fujimoto S
Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525
[TBL] [Abstract][Full Text] [Related]
23. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis.
Perez EA; Hack FM; Webber LM; Chou TC
Cancer Chemother Pharmacol; 1993; 33(3):245-50. PubMed ID: 8269606
[TBL] [Abstract][Full Text] [Related]
24. Potentiation by vitamin A of the action of anticancer agents against murine tumors.
Nakagawa M; Yamaguchi T; Ueda H; Shiraishi N; Komiyama S; Akiyama S; Ogata J; Kuwano M
Jpn J Cancer Res; 1985 Sep; 76(9):887-94. PubMed ID: 3932288
[TBL] [Abstract][Full Text] [Related]
25. Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo.
Gharehbaghi K; Szekeres T; Yalowitz JA; Fritzer-Szekeres M; Pommier YG; Jayaram HN
Life Sci; 2000 Nov; 68(1):1-11. PubMed ID: 11132239
[TBL] [Abstract][Full Text] [Related]
26. Acute effects of the heavy metal antidotes DMPS and DMSA on circulation, respiration, and blood homoeostasis in dogs.
Klimmek R; Krettek C; Werner HW
Arch Toxicol; 1993; 67(6):428-34. PubMed ID: 8215913
[TBL] [Abstract][Full Text] [Related]
27. Efforts to control the errant products of a targeted in vivo generator.
Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
Cancer Res; 2005 Jun; 65(11):4888-95. PubMed ID: 15930310
[TBL] [Abstract][Full Text] [Related]
28. [A novel Cisplatin delivery system for malignant ascites-bearing mice-a basic experimentation].
Itabashi T; Sugitachi A; Kimura Y; Ikeda M; Kumagai M; Matsuo T; Fujii H; Nishizuka S; Otsuka K; Koeda K; Sasaki A; Wakabayashi G
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2081-3. PubMed ID: 22202290
[TBL] [Abstract][Full Text] [Related]
29. [Lethal effects of nanoliposome encapsulated cisplatin on Saos-2 cells and its distribution in nude mice bearing human].
Wang GW; Guo W; Tang XD; Peng CL; Zhao H
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):525-30. PubMed ID: 19829667
[TBL] [Abstract][Full Text] [Related]
30. meso-2,3-dimercaptosuccinic acid monoalkyl esters: effects on mercury levels in mice.
Gale GR; Smith AB; Jones MM; Singh PK
Toxicology; 1993 Jul; 81(1):49-56. PubMed ID: 8396277
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system.
Light BW; Yu WD; McElwain MC; Russell DM; Trump DL; Johnson CS
Cancer Res; 1997 Sep; 57(17):3759-64. PubMed ID: 9288784
[TBL] [Abstract][Full Text] [Related]
32. Potentiation by squalene of the cytotoxicity of anticancer agents against cultured mammalian cells and murine tumor.
Nakagawa M; Yamaguchi T; Fukawa H; Ogata J; Komiyama S; Akiyama S; Kuwano M
Jpn J Cancer Res; 1985 Apr; 76(4):315-20. PubMed ID: 2408954
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous administration of sodium selenite and mercuric chloride decreases efficacy of DMSA and DMPS in mercury elimination in rats.
Juresa D; Blanusa M; Kostial K
Toxicol Lett; 2005 Jan; 155(1):97-102. PubMed ID: 15585364
[TBL] [Abstract][Full Text] [Related]
34. [A study of the oncolytic effect of a newly designed CDDP system on an experimental animal model with carcinomatous ascites].
Shindoh T; Matsuura N; Sugitachi A; Saitoh K
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2195-8. PubMed ID: 12484035
[TBL] [Abstract][Full Text] [Related]
35. Mononuclear platinum(II) complex with 2-phenylpyridine ligands showing high cytotoxicity against mouse sarcoma 180 cells acquiring high cisplatin resistance.
Okada T; El-Mehasseb IM; Kodaka M; Tomohiro T; Okamoto K; Okuno H
J Med Chem; 2001 Dec; 44(26):4661-7. PubMed ID: 11741483
[TBL] [Abstract][Full Text] [Related]
36. Effects of meso-2,3-dimercaptosuccinic acid or 2,3-dimercaptopropane 1-sulfonate on beryllium-induced biochemical alterations and metal concentration in male rats.
Flora SJ; Mathur S; Mathur R
Toxicology; 1995 Jan; 95(1-3):167-75. PubMed ID: 7825183
[TBL] [Abstract][Full Text] [Related]
37. pH sensitive polymeric complex of cisplatin with hyaluronic acid exhibits tumor-targeted delivery and improved in vivo antitumor effect.
Fan X; Zhao X; Qu X; Fang J
Int J Pharm; 2015 Dec; 496(2):644-53. PubMed ID: 26529576
[TBL] [Abstract][Full Text] [Related]
38. Structural characterization of Cd²⁺ complexes in solution with DMSA and DMPS.
Zeini Jahromi E; Gailer J; Pickering IJ; George GN
J Inorg Biochem; 2014 Jul; 136():99-106. PubMed ID: 24367995
[TBL] [Abstract][Full Text] [Related]
39. The effects of dimercaptosuccinic acid and other chelating agents on the retention of platinum in the rat kidney after treatment with cisplatin.
Planas-Bohne F; Shand E; Taylor DM
Cancer Chemother Pharmacol; 1982; 9(2):120-1. PubMed ID: 6293731
[TBL] [Abstract][Full Text] [Related]
40. A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.
Zhang B; Liu Y; Zhang P; Wei Y; Yin X; Zheng J
Int J Gynecol Cancer; 2011 Dec; 21(9):1540-6. PubMed ID: 22080895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
